<DOC>
	<DOCNO>NCT02476734</DOCNO>
	<brief_summary>In study investigator would like describe FDG-PET/CT response patient receive CART-19 immunotherapy Follicular Lymphoma ( FL ) , Diffuse Large B-cell Lymphoma ( DLBCL ) , Mantle Cell Lymphoma ( MCL ) part UPCC # 13413 . Subjects undergo two FDG-PET/CTs . One perform within 6 week CART-19 infusion repeat scan 1 month infusion .</brief_summary>
	<brief_title>FDG-PET/CT Imaging Early Predictor DP</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<criteria>Subjects enrol study UPCC 13413 Pilot Study Of Redirected Autologous T Cells Engineered To Contain AntiCd19 Attached To Tcr And 41bb Signaling Domains In Patients With Chemotherapy Resistant Or Refractory Cd19+ Lymphoma CART19 autologous Tcell trial relapse refractory DLBCL FL . As pilot study , plan enroll 4 subject two disease type interest . Subjects â‰¥ 18 year age Subjects able provide inform consent agree comply study procedure Subjects pregnant lactating . Subjects coenrolled study UPCC 13413 therefore must comply UPCC 13413 Pilot Study Of Redirected Autologous T Cells Engineered To Contain AntiCd19 Attached To Tcr And 41bb Signaling Domains In Patients With Chemotherapy Resistant Or Refractory Cd19+ Lymphoma requirement pertain pregnancy , lactation , conception contraception use throughout participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>REDIRECTED AUTOLOGOUS CART- 19 T-CELL IMMUNOTHERAPY</keyword>
</DOC>